In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Series of patients treated with sacubitril-valsartan in a cardiology day clinic: efficacy and safety after 6 months of follow-up

Session Poster Session 3

Speaker Cristina BELTRAN HERRERA

Event : Heart Failure 2019

  • Topic : heart failure
  • Sub-topic : Chronic Heart Failure: Pharmacotherapy
  • Session type : Poster Session

Authors : C Beltran Herrera (Madrid,ES), V Suberviola Sanchez-Caballero (Madrid,ES), S Briongos (Madrid,ES), M Sarrion (Madrid,ES), A Sanchez (Madrid,ES), C Cortina (Madrid,ES), A Estevez (Madrid,ES), ML Giganto (Madrid,ES), I Ponz (Madrid,ES), D Vaqueriza (Madrid,ES), M Dominguez (Madrid,ES), E Gomez (Madrid,ES), S Jimenez (Madrid,ES), L Mora (Madrid,ES), R Munoz (Madrid,ES)

Authors:
C Beltran Herrera1 , V Suberviola Sanchez-Caballero1 , S Briongos1 , M Sarrion1 , A Sanchez1 , C Cortina1 , A Estevez1 , ML Giganto1 , I Ponz1 , D Vaqueriza1 , M Dominguez1 , E Gomez1 , S Jimenez1 , L Mora1 , R Munoz1 , 1University Hospital Infanta Leonor - Madrid - Spain ,

Citation:

Introduction Sacubitril-valsartan (ARNI) has demonstrated to improve functional class (FC) by NYHA in patients (pts) with heart failure (HF) compared to ACEI with no higher complications rate. Our objective is to describe FC and real-life complications in pts treated with ARNI .Methods We  analyzed 63 pts, we evaluated FC by NYHA and complications (hypotension, impaired renal function and hyperkalemia) 3 and 6 months after ARNI. HF decompensations and drug withdrawals were evaluated after 6 months. Results:ARNI improves FC by NYHA at 3 and 6 months. There is no hypotension, impaired renal function or significant hyperkalemia at 3 and 6 months. 31.7% had history of HF in the 12 months before ARNI.  At 6 months there were only 5 HF, 2 with severe anemia as a trigger, 3 required admission and 2 were resolved on an outpatient basis. 2 drug withdrawals due to symptomatic hypotension and impaired renal function (Cr> 2.5 mg / dl) Conclusions:ARNI improves FC by NYHA without significant complications.There were a very small number of decompensations and drug withdrawals at 6 months.

MALES 51(81%)
AGE 70.52 (35--88)
HYPERTENSION 45 (71.4%)
DIABETES 32 (50.8%)
EF 30% (18-39)
Atrial Fibrilation 23 (36.5%)
Ischemic C. 34(54%)
DEVICES
DAI 20 (31.7%)
CRT 5 (7.9%)
DAI-CRT 21 (33.3%)
TREATMENT
BETABLOCKERS 60 ( 95.2%)
ACEI 46 (73%)
ARA-II 15 (23.8%)
MRA 40 (63.5%)
DIURETICS 43 (68.3%)
IVABRADINE 9 (14.3%)
DIGOXINE 5 (7.9%)

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are